Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Down 37.8% in March

Synaptogenix, Inc. (NASDAQ:SNPX) was the target of a large decrease in short interest in March. As of March 31st, there was short interest totalling 12,000 shares, a decrease of 37.8% from the March 15th total of 19,300 shares. Based on an average daily trading volume, of 12,200 shares, the short-interest ratio is currently 1.0 days. Approximately 0.9% of the shares of the company are sold short.

Institutional Trading of Synaptogenix

An institutional investor recently bought a new position in Synaptogenix stock. Geode Capital Management LLC purchased a new stake in shares of Synaptogenix, Inc. (NASDAQ:SNPX) in the fourth quarter, according to its most recent filing with the SEC. The firm purchased 10,844 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned 0.80% of Synaptogenix at the end of the most recent quarter. 10.34% of the stock is owned by institutional investors and hedge funds.

Synaptogenix Price Performance

SNPX opened at $2.24 on Thursday. Synaptogenix has a 12 month low of $1.84 and a 12 month high of $5.38. The stock has a market capitalization of $3.11 million, a P/E ratio of -0.21 and a beta of 1.07. The business has a 50 day simple moving average of $2.62 and a 200-day simple moving average of $2.92.

Synaptogenix (NASDAQ:SNPX) last released its earnings results on Thursday, March 27th. The company reported ($4.36) EPS for the quarter, missing analysts’ consensus estimates of ($2.06) by ($2.30).

Synaptogenix Company Profile

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease.